Literature DB >> 22077380

CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Jessica E Taaffe1, Steven E Bosinger, Gregory Q Del Prete, James G Else, Sarah Ratcliffe, Christopher D Ward, Thi Migone, Mirko Paiardini, Guido Silvestri.   

Abstract

BACKGROUND: CCR5 is a main co-receptor for HIV, but also homes lymphocytes to sites of inflammation. We hypothesized that inhibition of CCR5 signaling would reduce HIV-associated chronic immune activation.
METHODS: To test this hypothesis, we administered an antagonistic anti-CCR5 monoclonal antibody (HGS101) to five uninfected rhesus macaques (RMs) and monitored lymphocyte dynamics in blood and tissue.
RESULTS: CCR5 blockade resulted in decreased levels of CCR5+ T cells in blood and, at later timepoints, in lymph nodes. Additionally, the levels of CD25+ T cells increased in lymph nodes, but decreased in blood, bone marrow, and rectal mucosa. Finally, a profile of gene expression from HGS101-treated RMs revealed a subtle, but consistent, in vivo signature of CCR5 blockade that suggests a mild immune-modulatory effect.
CONCLUSIONS: Treatment with anti-CCR5 antibody induces changes in the tissue distribution of CCR5+ and CD25+ T cells that may impact on the overall levels of immune activation during HIV and SIV infection.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077380      PMCID: PMC3265632          DOI: 10.1111/j.1600-0684.2011.00521.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  118 in total

1.  A five-year longitudinal analysis of sooty mangabeys naturally infected with simian immunodeficiency virus reveals a slow but progressive decline in CD4+ T-cell count whose magnitude is not predicted by viral load or immune activation.

Authors:  Jessica Taaffe; Ann Chahroudi; Jessica Engram; Beth Sumpter; Tracy Meeker; Sarah Ratcliffe; Mirko Paiardini; James Else; Guido Silvestri
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

2.  Heat shock protein 60, via MyD88 innate signaling, protects B cells from apoptosis, spontaneous and induced.

Authors:  Michal Cohen-Sfady; Meirav Pevsner-Fischer; Raanan Margalit; Irun R Cohen
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

3.  Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Authors:  Jeffrey M Jacobson; Melanie A Thompson; Jacob P Lalezari; Michael S Saag; Barry S Zingman; Paul D'Ambrosio; Nancy Stambler; Yakov Rotshteyn; Andre J Marozsan; Paul J Maddon; Stephen A Morris; William C Olson
Journal:  J Infect Dis       Date:  2010-05-15       Impact factor: 5.226

4.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

5.  KLF2 transcription-factor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors.

Authors:  Michael A Weinreich; Kensuke Takada; Cara Skon; Steven L Reiner; Stephen C Jameson; Kristin A Hogquist
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

6.  Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys.

Authors:  Steven E Bosinger; Qingsheng Li; Shari N Gordon; Nichole R Klatt; Lijie Duan; Luoling Xu; Nicholas Francella; Abubaker Sidahmed; Anthony J Smith; Elizabeth M Cramer; Ming Zeng; David Masopust; John V Carlis; Longsi Ran; Thomas H Vanderford; Mirko Paiardini; R Benjamin Isett; Don A Baldwin; James G Else; Silvija I Staprans; Guido Silvestri; Ashley T Haase; David J Kelvin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

7.  CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells.

Authors:  Nichole R Klatt; Emi Shudo; Alex M Ortiz; Jessica C Engram; Mirko Paiardini; Benton Lawson; Michael D Miller; James Else; Ivona Pandrea; Jacob D Estes; Cristian Apetrei; Joern E Schmitz; Ruy M Ribeiro; Alan S Perelson; Guido Silvestri
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

Review 8.  New insights into the expanding complexity of the tumor suppressor ASPP2.

Authors:  Kerstin M Kampa; Michael Bonin; Charles D Lopez
Journal:  Cell Cycle       Date:  2009-09-08       Impact factor: 4.534

9.  Chemokine receptor 5Delta32 mutation reduces the risk of acute rejection in liver transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  Ann Transplant       Date:  2009 Jul-Sep       Impact factor: 1.530

10.  Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

Authors:  Jamal Suleiman; Barry S Zingman; Ricardo Sobhie Diaz; Jose Valdez Ramalho Madruga; Edwin DeJesus; Jihad Slim; Carmen Mak; Erin Lee; Michael C McCarthy; Lisa M Dunkle; Sharon Walmsley
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

View more
  7 in total

1.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.

Authors:  Sudhir Pai Kasturi; Pamela A Kozlowski; Helder I Nakaya; Matheus C Burger; Pedro Russo; Mathew Pham; Yevgeniy Kovalenkov; Eduardo L V Silveira; Colin Havenar-Daughton; Samantha L Burton; Katie M Kilgore; Mathew J Johnson; Rafiq Nabi; Traci Legere; Zarpheen Jinnah Sher; Xuemin Chen; Rama R Amara; Eric Hunter; Steven E Bosinger; Paul Spearman; Shane Crotty; Francois Villinger; Cynthia A Derdeyn; Jens Wrammert; Bali Pulendran
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.

Authors:  Thomas H Vanderford; Chloe Slichter; Kenneth A Rogers; Benton O Lawson; Rend Obaede; James Else; Francois Villinger; Steven E Bosinger; Guido Silvestri
Journal:  Blood       Date:  2012-05-01       Impact factor: 22.113

3.  HIV replication in conjunction with granzyme B production by CCR5+ memory CD4 T cells: Implications for bystander cell and tissue pathologies.

Authors:  Jacob Couturier; Alexander T Hutchison; Miguel A Medina; Cosmina Gingaras; Petri Urvil; Xiaoying Yu; Chi Nguyen; Parag Mahale; Lin Lin; Claudia A Kozinetz; Joern E Schmitz; Jason T Kimata; Tor C Savidge; Dorothy E Lewis
Journal:  Virology       Date:  2014-07-04       Impact factor: 3.616

4.  The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1.

Authors:  Jeffrey M Jacobson; Steven E Bosinger; Minhee Kang; Pablo Belaunzaran-Zamudio; Roy M Matining; Cara C Wilson; Charles Flexner; Brian Clagett; Jill Plants; Sarah Read; Lynette Purdue; Laurie Myers; Linda Boone; Pablo Tebas; Princy Kumar; David Clifford; Daniel Douek; Guido Silvestri; Alan L Landay; Michael M Lederman
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04-19       Impact factor: 2.205

Review 5.  Cytokine-Mediated Tissue Injury in Non-human Primate Models of Viral Infections.

Authors:  Cordelia Manickam; Spandan V Shah; Olivier Lucar; Daniel R Ram; R Keith Reeves
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

6.  CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.

Authors:  Xiao L Chang; Helen L Wu; Gabriela M Webb; Meenakshi Tiwary; Colette Hughes; Jason S Reed; Joseph Hwang; Courtney Waytashek; Carla Boyle; Cleiton Pessoa; Andrew W Sylwester; David Morrow; Karina Belica; Miranda Fischer; Scott Kelly; Nader Pourhassan; Rachele M Bochart; Jeremy Smedley; Christopher P Recknor; Scott G Hansen; Jonah B Sacha
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 8.786

7.  Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model.

Authors:  Riti Sharan; Shashank R Ganatra; Allison N Bucsan; Journey Cole; Dhiraj K Singh; Xavier Alvarez; Maya Gough; Cynthia Alvarez; Alyssa Blakley; Justin Ferdin; Rajesh Thippeshappa; Bindu Singh; Ruby Escobedo; Vinay Shivanna; Edward J Dick; Shannan Hall-Ursone; Shabaana A Khader; Smriti Mehra; Jyothi Rengarajan; Deepak Kaushal
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.